AMY MORIN: Open Payments
NPI 1629617469 · CEDAR RAPIDS, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,809 in 189 payments from 15 companies in 2025. Trend: 2023 $7,809 · 2024 $2,325 · 2025 $3,809
Food & beverage: $2,677Speaker / faculty: $1,125Education: $7
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $1,596 |
| Otsuka America Pharmaceutical, Inc. | 21 | $407 |
| Neurocrine BioSciences, Inc. | 39 | $384 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $284 |
| Teva Pharmaceuticals USA, Inc. | 14 | $202 |
| E.R. Squibb & Sons, L.L.C. | 13 | $198 |
| Alkermes, Inc. | 12 | $175 |
| Vanda Pharmaceuticals Inc. | 9 | $148 |
| Supernus Pharmaceuticals, Inc. | 9 | $141 |
| Lundbeck LLC | 3 | $77 |
Products named: VRAYLAR, INGREZZA, REXULTI, CAPLYTA, COBENFY, ARISTADA, AUSTEDO XR, FANAPT.
Industry payments across IA — which companies pay providers there.
